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Aims. To investigate the possible association of human papillomavirus (HPV) with endometrial hyperplasias and neoplasia. Does
HPV play any role in the initiation or prognosis of endometrial adenocarcinomas? Methods. Twenty-ﬁve endometrial adenocar-
cinomas of the endometrioid cell type, with and without squamous diﬀerentiation, and twenty-four endometrial hyperplasias of
variousforms(simple,complex, and atypical) were analyzed forthepresenceoftype16 and18 HPVbythepolymerasechain reac-
tion(PCR).Theresultswererelatedtohistopathologicalfeaturesofthetumour,andthepatients’age,andprognosis.Results.Sixof
25 endometrial adenocarcinomas were HPV 16-positive (24%), and 5 of 25 (20%) were HPV 18-positive. Simple endometrial hy-
perplasias was associated somewhat more commonly with HPV 16 and 18 (2/8 and 1/8 cases, resp.) than hyperplasias progressing
to endometrial adenocarcinomas, namely, atypical endometrial hyperplasia (1/8 and 0/8 cases, resp.). None of the positive cases in
the series, whether hyperplastic or neoplastic, demonstrated cytological evidence of HPV infection. There was no relation between
HPV-positive cases and squamous diﬀerentiation, depth of myometrial invasion, lymphatic involvement, lymphocytic response,
patients’ age, or prognosis. Conclusion. It appears that the presence of HPV in the endometrium, as detected by PCR, does not play
any role in the initiation or prognosis of endometrial adenocarcinoma.
Copyright © 2007 A. Giatromanolaki et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Human papillomavirus (HPV) infection in the female geni-
tal tract has been connected with speciﬁc sites: vulva, vagina,
cervix, and speciﬁc epithelium—the stratiﬁed squamous ep-
ithelium,leadingtoepithelialcellproliferationandoftenma-
lignancy.Theinfection,mostreliablydetectedbypolymerase
chain reaction (PCR), is recognized by distinct histological
changes in epithelial cells consisting of multinucleation and
koilocytosis [1, 2]. Typical examples of the hyperplastic pro-
cess include condylomata accuminata, and those of the neo-
plastic change include the intraepithelial neoplasias and the
squamous cell carcinomas of the vulva, vagina, and cervix.
In this context, HPV-infected cells have almost equated with
frankly malignant cells and, indeed, the Bethesda system
incorporated koilocytotic atypia and cervical intraepithelial
neoplasia grade I (CIN I) into one category, the low-grade
squamous intraepithelial lesions (LSIL), leading perhaps to
excisional cone biopsy [3].
A number of reports have demonstrated the presence of
HPV in endometrial adenocarcinomas [4–8], a tissue close
to, but lacking, the stratiﬁed squamous epithelium of the ex-
ocervix. Whether such tumours with glandular-type epithe-
lium may also exhibit morphological evidence of HPV in-
fection is not clear, as koilocytotic-like changes have hith-
erto been only reported in the squamoid component of some
endometrial adenocarcinomas [9, 10]. There is also some
dispute as to whether the presence of HPV in endometrial
tissues contributes to the development of endometrial neo-
plasms [6, 9, 11–13]. Thus far, we only know that HPV is un-
related to prognostic parameters and survival [7]; and there
is, of course, little information with regard to the viral pres-
ence in endometrial hyperplasias [4, 8].
In view of this paucity of information, this study was de-
signed to evaluate the presence of HPV in the endometrium
by PCR and its potential role in the genesis of endometrial
adenocarcinoma.
2. MATERIAL AND METHODS
The tissues used for this study were drawn from the ﬁles
of the Department of Pathology, Democritus University2 Infectious Diseases in Obstetrics and Gynecology
of Thrace Medical School (Alexandroupolis, Greece). They
were all hysterectomy specimens and had been routinely
ﬁxed in 10% formol-saline. The original haematoxylin and
eosin- (H and E-) stained sections consisted of 24 endome-
trial hyperplasias of various forms: simple (n = 8), complex
(n = 8), atypical (n = 8), and 25 endometrial adenocarci-
nomas: endometrioid cell type, G1, stage I, with (n = 5) and
without (n = 20) squamous diﬀerentiation.
The endometrioid adenocarcinomas and the various
forms of endometrial hyperplasia were typed along the lines
s u g g e s t e db yB u c k l eya n dF o x[ 14]. As G1 endometrioid ade-
nocarcinomaswereconsidered,onlythosecomposedintheir
entirety of glandular elements have no solid components,
other than squamous, and no nuclear atypia, other than low
grade[15]. The tumour stage was deﬁned according to FIGO
staging system [16]. None of the patients in the series had
previous history of vulvar, vaginal, or cervical HPV-related
lesion, intraepithelial neoplasia, or carcinoma. The duration
o ff o l l o wu pw a s5y e a r sa tl e a s t .
The tissues were analysed for the presence of type 16 and
18 HPV by PCR ampliﬁcation (Laboratory of Second De-
partment of Internal Medicine), Democritus University of
Thrace Medical School (Alexandroupolis, Greece).
2.1. DNAextraction
Paraﬃns e c t i o n sw e r ec u ta t7 µm and nonhyperplastic or
nonmalignant tissue was trimmed away from the sample us-
ing parallel (H and E-) stained sections as a guide [17]. Nor-
mal sections were also cut and served as negative controls.
Vigorous preparations were taken to avoid sample contami-
nation. This was achieved by cleansing the microtome with
75% ethanol before and after cutting up each paraﬃn block,
and using sterilized stainless forceps for transferring the sec-
tions.Paraﬃnwaxwasremovedwithxylene,andthesamples
were subsequently washed with 100% ethanol (the two steps
repeated twice). DNA was isolated from the resuspended tis-
sue using a commercially available kit, according to the man-
ufacturer’s instructions (QIAamp DNA Mini Kit, QIAGEN
Inc, Calif, USA). The human p53 and VEGF genes were used
as controls to test the ampliﬁcation ability of the extracted
DNAs.
2.2. DetectionofHPV
Isolated DNA was subjected to GP5+/GP6+ PCR [18].
Brieﬂy, standard PCRs were carried out in 50µLc o n -
taining 50mM KCl, 10mM Tris HCL (pH 8.3), 200µM
each dNTP, 3.5µMM g C l 2, 1 U Platinum Taq Polymerase
(Gibco, BRL, USA), and 50pmol each of the GP5+
(5
 -TTTGTTACTGTGGTAGATACTAC-3
 )a n dG P 6 +
(5
 -GAAAAATAAACTGTAAATCATATTC-3
 )p r i m e r s .
Polymerase chain reaction ampliﬁcation conditions were
96◦C( 1m i n u t e ) ,4 5 ◦C (1.5 minutes) and 72◦C( 1m i n u t e )
for 40 cycles, followed by ﬁnal extension at 72◦Cf o r1 0
minutes.
Single PCR was carried out using type-speciﬁc primers
to investigate the incidence of both HPV 16 and HPV 18
sequences in GP5+/GP6+ samples (Cheng et al., 1995).
Table 1: HPV detection in hyperplastic and neoplastic en-
dometrium.
Endometrium HPV 16 HPV 18 HPV 16 and 18
Simple hyperplasia 2/8 (25%) 1/8 (12.5%) —
Complex hyperplasia 1/8 (12.5%) 0/8 —
Atypical hyperplasia 1/8 (12.5%) 0/8 —
Adenocarcinoma 3/25 (12%) 2/25 (8%) 3/25 (12%)
Total adenocarcinomas 6/25 (24%)5 / 2 5 ( 2 0 %) —
The HPV 16 speciﬁc primers were as follows: Forward:
5
 -CCCAGCTGTAATCATGCATGGAGA-3
  and Reverse: 3
 -
CACACGGGTAATTCAGAAGGT-5
  generating a 253bps







ating a 201bps PCR product. PCR ampliﬁcation was car-
riedoutin25µLﬁnalvolumecontaining50mMKCl,10mM
Tris-HCl (pH8.3), 1.5µMM g C l 2, 200µMe a c hd N T P ,a n d1
U Platinum Taq Polymerase (Gibco, BRL, US). Polymerase
chain reaction ampliﬁcation conditions were 96◦C( 3 0s e c -
onds), 60◦C( 3 0s e c o n d s ) ,a n d7 2 ◦C (30 seconds) for 35 cy-
cles, followed by ﬁnal extension at 72◦Cf o r1 0m i n u t e s .
The ampliﬁcations were carried out in a Mastercycler
gradient(Eppendorf-Netheler-HinzGmbH,Hamburg,Ger-
many) thermal cycler and the PCR products were visualized
in ethidium bromide stained agarose gels (2%).
In all PCR assays, appropriate positive controls for HPV
16 (human Caski cell line DNA), HPV 18 (human HeLA cell
line DNA), and cervical squamous cell carcinomas were used
and identiﬁed. In addition, the commercially provided pos-
itive controls for the identiﬁcation of HPV 16 and HPV 18
by Maxim Biotech, Inc (San Francisco, Calif, USA) were ap-
plied successfully. Human lung and liver tissues were tested
as negative controls and were consistently negative. All reac-
tions were performed in a “blinded” manner by DP.
2.3. Statistics
Statistical analysis of the data was performed using Fisher’s
exact test (SPSS, version 11.0.1).
3. RESULTS
Human papillomavirus (HPV) 16 was a somewhat more
common inhabitant than HPV 18 in endometrial neoplasms
and in all forms of endometrial hyperplasia. It was detected
in 24% (versus 20% of HPV 18) of the endometrial ade-
nocarcinomas studied, and in 16.6% (versus 4% of HPV
18) of the endometrial hyperplasias (Table 1). Both types of
HPV occurred preferentially in simple endometrial hyper-
plasia rather than in complex or atypical hyperplasia, and
there were three invasive endometrial neoplasms that were
positive for both HPV 16 and 18. Interestingly, HPV were
detected with approximately equal frequency in endometrial
adenocarcinomas with squamous diﬀerentiation (1 in 5) and
those without squamous elements (4-5 in 20) (Table 1).A. Giatromanolaki et al. 3
Figure 1: Agarose gel analysis of endometrial adenocarcinomas by
PCR using HPV 16 type-speciﬁc primers. Line 1 (marker 100bps),
lines 2, 3, 6 (positive samples), lines 4, 5 (negative samples), line 7
(negative control), and line 8 (positive control).
Figure 2: Agarose gel analysis of endometrial adenocarcinomas by
PCR using HPV 18 type-speciﬁc primers. Line 1 (marker 100bps),
lines 2, 4 (positive samples), lines 3, 5, 6 (negative samples), line 7
(negative control), and line 8 (positive control).
Detection of HPV 16/18 DNA sequences in primary en-
dometrial adenocarcinomas by PCR ampliﬁcation products
in representative specimens are shown in Figures 1 and 2,r e -
spectively.
None of the HPV 16 and 18-positive cases, whether hy-
perplastic or neoplastic, demonstrated cellular evidence of
viralinfection,thatis,koilocytoticatypiaormultinucleation.
There was no statistical correlation between HPV 16/18
andsquamousdiﬀerentiation,depthofmyometrialinvasion,
lymphatic involvement, lymphocytic response, patients’ age,
or survival (data not shown).
4. DISCUSSION
Thedetectionofhumanpapillomavirus(HPV)inthehuman
endometrium, whether hyperplastic or neoplastic, is fraught
with curiosities. HPV was thought as being site- and tissue-
speciﬁc, infecting the stratiﬁed squamous epithelium of the
lower female genital tract: vulva, vagina, and exocervix [19],
most commonly in connection with condylomata accumi-
nata,intraepithelialneoplasias,andinvasivecarcinomas,and
thattheinfectedtissuessuﬀeredthecytopathiceﬀectofmult-
inucleation and koilocytotic atypia. Still, HPV 16 and 18, as
detected by PCR, appear to reside in the endometrium, a
simple or pseudostratiﬁed epithelium columnar in type, cil-
iated, in part, lining glands or glandular structures, and not
having the characteristic cellular changes of HPV infection
[1, 2]. Furthermore, the glandular lesions of the endocervix
(adenocarcinomainsitu,invasiveadenocarcinoma)mayalso
harbour HPV 16 and 18 without morphological evidence of
multinucleation or koilocytotic atypia [20–22].
Detecting HPV DNA sequences in tissues originally ﬁxed
in formaldehyde and embedded in paraﬃnw a xm a yp r o v e
diﬃcult by PCR methods [18], and the results obtained are
inconsistent, as both speciﬁcity and sensitivity of various
HPV PCR primer sets are not unaﬀected by intermethod
variations [23]. This is reﬂected in the reported incidence of
HPV 16/18 DNA detection in endometrial adenocarcinomas
ranging from 4% to 37.5% [4–8]. Our results fall somewhere
in the middle of this range (24% for HPV 16, and 20% for
HPV 18) and are irrespective of the presence or otherwise of
squamous diﬀerentiation.
Given that HPV infection precedes the development of
cancer [24], it is also intriguing that HPV was detected less
frequently in endometrial hyperplasias progressing to ade-
nocarcinomas, namely atypical hyperplasia, than those not
related to such development, namely simple endometrial-
hyperplasia, and in carcinoma. This apparently means that
HPV cannot initiate oncogenic events in the endometrium
through the sequence atypical hyperplasia-neoplasia. Sim-
ilarly low or even lower, almost negligible, incidence of
HPV infection for atypical hyperplasia were reported earlier
[4, 8].
Interestingly, the presence of HPV in endometrial neo-
plasms was unrelated to histopathological features, patients’
age, or patients’ survival. This is also the experience of other
investigators [8]. It is rather odd, however, that geograph-
ical/environmental conditions may inﬂuence the frequency
of HPV detection; HPV 16 was detected in 6/47 (13%) en-
dometrioidadenocarcinomafromJapanand2/38(5%)from
theUnitedStates[4].OthersfailedtodetectHPVDNAinen-
dometrial carcinomas [25–28], despite employing relatively
large number of cases (66 in one study) and tumours with
squamous cell elements (adenocarcinomas with squamous
diﬀerentiation, squamous cell carcinomas) [26]o rc e r v i c a l
tissues with stage II endometrial adenocarcinomas [28]; they
suggested that the absence of HPV from the malignant en-
dometrium is a hallmark of endometrial, as opposed to en-
docervical adenocarcinomas [28, 29].
Since HPV 16/18 infection is, by and large, site- and
tissue-speciﬁc (vulva, vagina, and cervix stratiﬁed squamous
epithelium), the endometrium, as indeed the glandular le-
sions of the endocervix, may not be a suitable host for HPV
replication and maturation. This is further supported by
the absence of relevant epithelial changes, lack of correla-
tion with histological features or prognosis, and the low in-
cidence rates with precancerous endometrial lesions. There
is, of course, some evidence that koilocytotic-like changes
may occur in the squamoid component of some endome-
trial adenocarcinomas with squamous diﬀerentiation [9, 10]
and it is perhaps possible that at this site HPV positiv-
ity is preferentially present [30]. Nonetheless, the spread of
HPV in the endometrium is not uncommon [4–8]a n ds e v -
eral cases in our material were positive for both HPV 16.
We believe, as others do [9], that HPV, originated from
the lower genital tract, represents a mere “passenger” in
the endometrium, residing in its simple or pseudostrat-
iﬁed columnar epithelium and having no aetiological or
pathogenic role in the development of endometrial adeno-
carcinoma.4 Infectious Diseases in Obstetrics and Gynecology
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